Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.06% | 14.23% | 21.88% | 30.36% | 48.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.92% | 15.89% | 11.82% | 32.24% | 34.49% |
| Operating Income | -22.92% | -15.89% | -11.82% | -32.24% | -34.49% |
| Income Before Tax | -26.61% | -19.15% | -14.66% | -43.03% | -31.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.61% | -19.15% | -14.66% | -43.03% | -31.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.61% | -19.15% | -14.66% | -43.03% | -31.58% |
| EBIT | -22.92% | -15.89% | -11.82% | -32.24% | -34.49% |
| EBITDA | -23.33% | -16.15% | -11.85% | -32.57% | -34.70% |
| EPS Basic | -13.14% | -5.96% | -2.17% | -31.69% | 10.03% |
| Normalized Basic EPS | -13.14% | -5.94% | -2.19% | -31.63% | 10.01% |
| EPS Diluted | -13.14% | -5.96% | -2.17% | -31.69% | 10.03% |
| Normalized Diluted EPS | -13.14% | -5.94% | -2.19% | -31.63% | 10.01% |
| Average Basic Shares Outstanding | 11.92% | 12.45% | 12.22% | 8.64% | 46.23% |
| Average Diluted Shares Outstanding | 11.92% | 12.45% | 12.22% | 8.64% | 46.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |